Four-year study of entecavir efficacy and safety in nucleos (T)ide-naïve HBeAg positive chronic hepatitis B patients

Basit Öğe Kaydı
dc.contributor.authorCelen M.K.
dc.contributor.authorDal T.
dc.contributor.authorAyaz C.
dc.contributor.authorBayan K.
dc.contributor.authorMert D.
dc.contributor.authorDeveci O.
dc.contributor.authorOruc E.K.
dc.date.accessioned2024-04-24T18:46:10Z
dc.date.available2024-04-24T18:46:10Z
dc.date.issued2014
dc.departmentDicle Üniversitesien_US
dc.description.abstractEntecavir is a guanosine analogue with activity against hepatitis B virus. The aim of this 4-year trial was to evaluate entecavir treatment in nucleos(t)ide-naïve HBeAg-positive chronic hepatitis B patients. Forty-nine patients received entecavir and nine of them withdrew from the trial at the end of week 96. The initial mean value of alanine aminotransferase was 79.4±41.5 IU/L, and at the end of the 4-year study period, 90% of patients had alanine aminotransferase values within the normal range. At week 96, 91.7% of patients had HBV DNA <300 copies; at month 48, 90% of patients had HBV DNA <50 IU/mL. HBeAg loss was recorded in 7.1% of patients at week 96 and in 12.5% at month 48. The rate of HBeAg seroconversion was 4.8% at week 96 and 7.5% at month 48. The rate of HBsAg seroconversion was 2.1% at week 96 and 2.5% at month 48. Entecavir as a potent and safe agent leading to continuous viral suppression proved to be safe and well tolerated therapy.en_US
dc.identifier.endpage36en_US
dc.identifier.issn0353-9466
dc.identifier.issue1en_US
dc.identifier.pmid24974664
dc.identifier.scopus2-s2.0-84904581727
dc.identifier.scopusqualityQ3
dc.identifier.startpage31en_US
dc.identifier.urihttps://hdl.handle.net/11468/25094
dc.identifier.volume53en_US
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherKlinicka Bolnica Sestre Milosrdniceen_US
dc.relation.ispartofActa Clinica Croatica
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAntiviral Agents - Therapyen_US
dc.subjectChronicen_US
dc.subjectGuanine - Therapeutic Useen_US
dc.subjectHepatitis Ben_US
dc.titleFour-year study of entecavir efficacy and safety in nucleos (T)ide-naïve HBeAg positive chronic hepatitis B patientsen_US
dc.titleFour-year study of entecavir efficacy and safety in nucleos (T)ide-naïve HBeAg positive chronic hepatitis B patients
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu